Yeung, K. T., Isaacs, C., Howard-Mcnatt, M., Yau, C., Chien, J., Wallace, A. M., Boughey, J. C., Han, H. S., Borges, V. F., Falkson, C. I., Yee, D., Omene, C., Nanda, R., Chapple, A., Perlmutter, J., Pohlmann, P. R., Borowsky, A. D., Symmans, W. F., Veer, L. V., Esserman, L. (2026). Neoadjuvant DAN-222 plus niraparib in high-risk HER2-negative breast cancer: Results from the I-SPY 2 adaptive platform trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.625